Navigation Links
Anemia Drugs May Raise Death Risk in Cancer Patients
Date:4/30/2009

Latest findings support recent label warnings for Procrit, Aranesp, experts say,,

THURSDAY, April 30 (HealthDay News) -- Two new studies provide more evidence that drugs such as Procrit and Aranesp, often used by cancer patients to fight anemia-linked fatigue, may boost the risk of death and serious adverse events such as blood clots.

These drugs, called erythropoiesis-stimulating agents (ESAs), have also been associated in prior studies with increased risk of heart attack, stroke and tumor growth. The primary argument for the continued use of these drugs is that they help reduce the number of blood transfusions some cancer patients need, while improving quality of life.

However, a co-author of one paper, Dr. Anthony Reiman, from the University of Alberta, Canada, said his team is "supporting other groups that are recommending great caution in using these drugs for cancer patients, and in routine circumstances they may not be indicated. We hope the drugs would still be made available for people for whom transfusion isn't a good option -- but those are very limited circumstances."

ESAs include erythropoietin (Epogen, Procrit) and darbepoetin (Aranesp). They work by stimulating the bone marrow to produce new red blood cells, according to the U.S. National Institutes of Health. They are used to treat anemia caused by chemotherapy and to treat anemia in people with chronic kidney disease who are on dialysis.

But rising concern led the U.S. Food and Drug Administration in 2007 to ask the drugs' manufacturers to add a "black box" warning to the medications. The warning indicates that the medications should be used at the lowest possible doses to avoid risks such as blood clots, heart attacks, stroke, congestive heart failure, increased tumor growth and an increased risk of death. The FDA also recommended that the medications be prescribed at the lowest doses possible because trials generally indicated an increa
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Controversial Anemia Drug Doesnt Cut Need for Transfusions
3. Cancer Doctors Across America Stunned at Governments Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling Interference in Practice of Medicine
4. Simpler Anemia Treatment May Help Kidney Patients
5. FDA Issues New Warnings for Anemia Drugs
6. New anemia measure predicts risk of death in dialysis patients
7. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
8. New Kind of Stem Cells Reverse Sickle Cell Anemia
9. Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
10. Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia
11. FDA Reports New Risks Posed by Anemia Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anemia Drugs May Raise Death Risk in Cancer Patients
(Date:9/23/2014)... New York, N.Y. (PRWEB) September 23, 2014 ... supplement to join the Royal Sport LTD family of ... 100 calories and 20g of pure Whey protein without ... , This ‘Ultra Clean’ protein is available on shelves ... Royal Sport LTD website—where the brand is offering a ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... is the process of translating the entire verbal ... therapeutic procedures, and prognosis, into a readable textual ... patients, and healthcare providers. With attending physicians unable ... patient’s condition, outsourcing of such documentation to medical ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert Jim ... a 13-year veteran in the school, commercial and transit bus ... Sales of Colton, California. While with A-Z Mr. Reynolds was ... revenues, profit and market penetration by double digits. , ADOMANI ... or plug-in hybrid vehicle conversions. They have converted a ...
(Date:9/23/2014)... September 23, 2014 If you or ... dressing for the treatment may be a challenge. Fortunately, ... of garment that is designed to improve the experience. ... receive dialysis without having to remove, tear or reposition ... privacy and preserving their dignity. At the same time, ...
(Date:9/23/2014)... Airbus Helicopters Inc. (AHI) is proud to ... 2014 Vision Zero Aviation Safety Award recipient ... free flight safety service the company provides the air ... Medical Specialist for Airbus Helicopters Inc., presented Protean CEO ... the Air Medical Transport Conference Annual Community Awards banquet ...
Breaking Medicine News(10 mins):Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4
... can be severe , , MONDAY, May 18 (HealthDay News) -- ... as it tries to serve the poor, researchers from North ... recovering from breast cancer do not take the drugs ... do not follow instructions to take these drugs, medications that ...
... CLC 27th Annual Conference on Professional Issues May 24 in ... Council, the leading nonprofit professional association serving child life specialists, ... recipient of the 2009 Distinguished Service Award, in recognition of ... Utica College was selected by ...
... retail locationNORTH BERGEN, N.J., May 18 Eco Shoppe has announced ... Eco Shoppe store in the country. Eco Shoppe is a ... products directly to consumers through exciting new stores as well as ... will open in Austin on May 21 and is owned and ...
... made on May 13, 2009, as Minnesota became the ... health provider into state statute - enabling students who ... model to become licensed to practice. The Minnesota ... a bill establishing the Dental Therapist and Advanced Dental ...
... Study Confirms Previous Positive Findings on Efficacy and ... Deutsche Bank 34th Annual Healthcare Conference Today at ... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... from its Phase IIb clinical trial known as ...
... study finds , , MONDAY, May 18 (HealthDay News) -- People ... chance of living a longer and healthier life. , Researchers ... data from 2002 to 2007, found that that wealthier people ... were less likely to have depression, high-blood pressure or diabetes ...
Cached Medicine News:Health News:Poor Women Seem to Be Skipping Breast Cancer Drugs 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 3Health News:First Eco Shoppe Opening in Austin on May 21 2Health News:First Eco Shoppe Opening in Austin on May 21 3Health News:First Eco Shoppe Opening in Austin on May 21 4Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 2Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 4Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 5Health News:Money May Matter, Health-Wise, in Old Age 2
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Rising health concerns, growing risk ... of foreign and domestic players in the market are ...   The India Probiotic market ... potential markets worldwide due to multiple factors such as ... changing food consumption patterns, increasing diabetic population, growing risk ...
(Date:9/23/2014)... 23, 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of ... Lary, who will serve on Medimetriks, Audit Committee, ... to the Company.  Mr. Lary is currently Managing ... leading institutional investment firm.  Mr. Lary is responsible ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2
... N.J., Oct. 31, 2011 Johnson & Johnson Pharmaceutical ... has submitted a supplemental New Drug Application (sNDA) to ... ® ER (tapentadol) extended-release tablets, an oral analgesic, ... peripheral neuropathy (DPN) in adults. The FDA approved NUCYNTA ...
... NEW YORK, Oct. 31, 2011 Reportlinker.com ... is available in its catalogue: ... 2016 http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... to 2016 Summary ...
Cached Medicine Technology:Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 3Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 4Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 5Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 6Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 7Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 8Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 9Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 10Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 11Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 12Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 13Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... small bench top chemistry analyzer that utilizes dry ... with results available within 8 - 15 minutes. ... instrument accepts whole blood samples and is calibrated ... At the conclusion of testing, results are available ...
... is a battery-backed up, microprocessor based, quality instrument ... It stores and displays a chart on its ... scrolled through or zoomed into and out of, ... to 3 months can be seen at one ...
Medicine Products: